Tirzepatide vs GLP-1: What Makes It Different
Without enough protein, weight loss can come from muscle rather than fat which harms metabolism long-term
Retatrutide Masterclass: Clinical Trials, Mechanism of Action, Weight Loss Data and What the Research Really Shows Retatrutide is one of the most advanced metabolic peptides currently in research, with clinical trials showing up to ~24% body weight reduction over 48 weeks
The results demonstrated that the 25mg daily pill delivered clinically meaningful weight loss: Average weight loss of 13.6-16.6% compared to 2.2-2.7% with placebo 76% of participants achieved at least 5% weight loss versus 31% on placebo Over 30% achieved 20% or greater weight loss Significant improvements in blood pressure, cholesterol, and inflammatory markers These results are comparable to what weve seen with injectable Wegovy, which typically produces 12-15% weight loss
Although exact dosing schedules may vary depending on the final approved formulation, it is likely that retatrutide will follow a similar model to other GLP-1 and dual-agonist drugs, increasing in small amounts during the first few months of treatment
The most frequent injuries involve long-term digestive problems, inflammation of the pancreas, gallbladder disease, kidney injury, and growing concerns about thyroid tumors